Heptares to Present at Upcoming Scientific and Biotech Industry Conferences

WELWYN GARDEN CITY, England and BOSTON, September 6, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that it will be presenting at the following scientific conferences and biotech industry events over the coming weeks.

6^th CNS Partnering and Deal-making conference (Boston, MA, USA, 9-10 September)

Dan Grau, Heptares' President, will give a presentation entitled "Go to Market or Build for Pharma? A Biotech Perspective on Neuroscience" (2:15pm Eastern time on 9 September). Mr Grau will also chair a panel on "Investment Opportunities with Venture Capital" (5:00pm, 9 September) and participate in a panel discussion on "Current and Future Trends in CNS Development" (2:10pm, 10 September).

17^th RSC / SCI Medicinal Chemistry Symposium (Cambridge, UK, 9-11 September)

Miles Congreve will present a talk entitled "Identification of Orexin Antagonists for the Treatment of Insomnia and Addiction using Structure-Based Drug Design" (11:00am UK time, 9 September).

Discovery on Target (Boston, MA, 24-26 September)

Dan Grau will give a presentation entitled "Prioritizing Dementia Indications for a Novel Cognition Drug: A Case Study for Selective Muscarinic Agonists," (9:10am ET, 26 September) as part of the GPCR Targeted Therapies track.

In addition, Cath Hutchings, Antibody Project Manager at Heptares, will present on "Using Stabilized Receptors to Generate Therapeutic Antibodies to GPCR Targets" (4:30pm ET, 26 September) as part of the Antibodies Against Membrane Protein Targets (Part Two) track.

13th Annual Biotech in Europe Investor Forum (Zurich, Switzerland, 30 September - 1 October)

Malcolm Weir, Heptares CEO, will participate in a panel discussing recent trends in Neuroscience drug discovery and development (10:30am Central European Summer Time, 30 September) and will also present an overview of the Company at 2:15pm CEST on the same day.

3rd Central European Life Science Investment Conference (Krakow, Poland, 17-18 October)

Barry Kenny, Heptares' Chief Business Officer, will participate in a panel discussion on International Collaboration, entitled "Winning the Deal and Subsequent Collaboration: the Do's and Don'ts" (2:45pm CEST, 17 October)

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune, Morphosys, Takeda and Cubist, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com

SOURCE Heptares Therapeutics